Biological, Preclinical and Clinical Characteristics of Inhibitors of Vascular Endothelial Growth Factors

被引：34

作者：

Chong, Victor ^{[1
]}

机构：

[1] Oxford Univ Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England

来源：

OPHTHALMOLOGICA | 2012年 / 227卷

关键词：

Age-related macular degeneration; Avastin; Diabetic macular edema; EYLEA; Lucentis; Macugen; Vascular endothelial growth factors; ANTI-VEGF ANTIBODY; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; IRIS NEOVASCULARIZATION; NONHUMAN PRIMATE; TYROSINE KINASE; SOLID TUMORS; FELLOW EYES; IN-VITRO; RANIBIZUMAB;

D O I：

10.1159/000337152

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Vascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. The discovery of anti-VEGF agents has revolutionized our treatment of these conditions. There are 4 anti-VEGF agents that are either approved or in common use in ophthalmology, namely pegaptanib (Macugen, Pfizer), ranibizumab (Lucentis, Novartis), aflibercept or VEGF Trap-Eye (EYLEA, Bayer) and bevacizumab (Avastin, Roche). There are differences between them. In this review, the differences are discussed in detail. Furthermore, an attempt is made to explain some of the clinical trial data based on their differences in ocular efficacy, duration of action, and local and systemic safety concerns. Copyright (C) 2012 S. Karger AG, Basel

引用

页码：2 / 10

页数：9

共 52 条

[1] The role of vascular endothelial growth factor \in ocular health and disease [J].

Adamis, AP ;

Shima, DT .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (02) :111-118

[2] Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate [J].

Adamis, AP ;

Shima, DT ;

Tolentino, MJ ;

Gragoudas, ES ;

Ferrara, N ;

Folkman, J ;

DAmore, PA ;

Miller, JW .

ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) :66-71

[3] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[4]

[Anonymous], 2011, REG PHARM VEGF TRAP

[5]

Baca M, 1997, J BIOL CHEM, V272, P10678

[6] Pharmacokinetics of intravitreal ranibizumab (Lucentis) [J].

Bakri, Sophie J. ;

Snyder, Melissa R. ;

Reid, Joel M. ;

Pulido, Jose S. ;

Ezzat, Mohamed K. ;

Singh, Ravinder J. .

OPHTHALMOLOGY, 2007, 114 (12) :2179-2182

[7] Pharmacokinetics of intravitreal bevackumab (avastin) [J].

Bakri, Sophie J. ;

Snyder, Melissa R. ;

Reid, Joel M. ;

Pulido, Jose S. ;

Singh, Ravinder J. .

OPHTHALMOLOGY, 2007, 114 (05) :855-859

[8] Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the MARINA and ANCHOR Trials [J].

Barbazetto, Irene A. ;

Saroj, Namrata ;

Shapiro, Howard ;

Wong, Pamela ;

Ho, Allen C. ;

Freund, K. Bailey .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 149 (06) :939-946

[9] Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].

Brown, David M. ;

Kaiser, Peter K. ;

Michels, Mark ;

Soubrane, Gisele ;

Heier, Jeffrey S. ;

Kim, Robert Y. ;

Sy, Judy P. ;

Schneider, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444

[10] Pharmacokinetics [J].

Byeon, Suk Ho ;

Kang, Sung Yong .

OPHTHALMOLOGY, 2009, 116 (01) :168-169

← 1 2 3 4 5 6 →